Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis

Stella De Nicola, Alessio Aghemo, Maria Rosaria Campise, Roberta D'Ambrosio, Maria Grazia Rumi, Piergiorgio Messa, Massimo Colombo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Mixed cryoglobulinemia (MC), the most common extra-hepatic manifestation of HCV, may lead to renal involvement ranging from mild urinary abnormalities to nephritic syndrome, eventually evolving to renal failure requiring renal replacement therapy. HCV eradication with pegylated interferon (PEG-IFN) and ribavirin (RBV) is the only curative treatment for MC-related membranoproliferative glomerulonephritis. The addition of directly acting antivirals (DAAs) to PEG-IFN and RBV has significantly improved sustained virological response rates in HCV genotype 1 patients. Safety and efficacy of this regimen in patients with membranoproliferative glomerulonephritis has not been proved yet. Here, we report the case of a woman with HCV-1-related cryoglobulinemic membranoproliferative glomerulonephritis presenting with severe nephritic syndrome and rapidly progressive renal failure, who received successful treatment with the DAA telaprevir in conjunction with PEG-IFN and RBV. Triple therapy was safe and effective, leading to HCV eradication and complete resolution of acute renal failure.

Original languageEnglish
Pages (from-to)527-531
Number of pages5
JournalAntiviral Therapy
Volume19
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Membranoproliferative Glomerulonephritis
Ribavirin
Chronic Hepatitis C
Glomerulonephritis
Interferons
Cryoglobulinemia
Kidney
Renal Insufficiency
Antiviral Agents
Renal Replacement Therapy
Acute Kidney Injury
Therapeutics
Genotype
Safety
Liver
telaprevir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases
  • Medicine(all)

Cite this

Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. / De Nicola, Stella; Aghemo, Alessio; Campise, Maria Rosaria; D'Ambrosio, Roberta; Rumi, Maria Grazia; Messa, Piergiorgio; Colombo, Massimo.

In: Antiviral Therapy, Vol. 19, No. 5, 2014, p. 527-531.

Research output: Contribution to journalArticle

@article{8fa5627eb5214227aff1c49cc65c3e31,
title = "Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis",
abstract = "Mixed cryoglobulinemia (MC), the most common extra-hepatic manifestation of HCV, may lead to renal involvement ranging from mild urinary abnormalities to nephritic syndrome, eventually evolving to renal failure requiring renal replacement therapy. HCV eradication with pegylated interferon (PEG-IFN) and ribavirin (RBV) is the only curative treatment for MC-related membranoproliferative glomerulonephritis. The addition of directly acting antivirals (DAAs) to PEG-IFN and RBV has significantly improved sustained virological response rates in HCV genotype 1 patients. Safety and efficacy of this regimen in patients with membranoproliferative glomerulonephritis has not been proved yet. Here, we report the case of a woman with HCV-1-related cryoglobulinemic membranoproliferative glomerulonephritis presenting with severe nephritic syndrome and rapidly progressive renal failure, who received successful treatment with the DAA telaprevir in conjunction with PEG-IFN and RBV. Triple therapy was safe and effective, leading to HCV eradication and complete resolution of acute renal failure.",
author = "{De Nicola}, Stella and Alessio Aghemo and Campise, {Maria Rosaria} and Roberta D'Ambrosio and Rumi, {Maria Grazia} and Piergiorgio Messa and Massimo Colombo",
year = "2014",
doi = "10.3851/IMP2684",
language = "English",
volume = "19",
pages = "527--531",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "5",

}

TY - JOUR

T1 - Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis

AU - De Nicola, Stella

AU - Aghemo, Alessio

AU - Campise, Maria Rosaria

AU - D'Ambrosio, Roberta

AU - Rumi, Maria Grazia

AU - Messa, Piergiorgio

AU - Colombo, Massimo

PY - 2014

Y1 - 2014

N2 - Mixed cryoglobulinemia (MC), the most common extra-hepatic manifestation of HCV, may lead to renal involvement ranging from mild urinary abnormalities to nephritic syndrome, eventually evolving to renal failure requiring renal replacement therapy. HCV eradication with pegylated interferon (PEG-IFN) and ribavirin (RBV) is the only curative treatment for MC-related membranoproliferative glomerulonephritis. The addition of directly acting antivirals (DAAs) to PEG-IFN and RBV has significantly improved sustained virological response rates in HCV genotype 1 patients. Safety and efficacy of this regimen in patients with membranoproliferative glomerulonephritis has not been proved yet. Here, we report the case of a woman with HCV-1-related cryoglobulinemic membranoproliferative glomerulonephritis presenting with severe nephritic syndrome and rapidly progressive renal failure, who received successful treatment with the DAA telaprevir in conjunction with PEG-IFN and RBV. Triple therapy was safe and effective, leading to HCV eradication and complete resolution of acute renal failure.

AB - Mixed cryoglobulinemia (MC), the most common extra-hepatic manifestation of HCV, may lead to renal involvement ranging from mild urinary abnormalities to nephritic syndrome, eventually evolving to renal failure requiring renal replacement therapy. HCV eradication with pegylated interferon (PEG-IFN) and ribavirin (RBV) is the only curative treatment for MC-related membranoproliferative glomerulonephritis. The addition of directly acting antivirals (DAAs) to PEG-IFN and RBV has significantly improved sustained virological response rates in HCV genotype 1 patients. Safety and efficacy of this regimen in patients with membranoproliferative glomerulonephritis has not been proved yet. Here, we report the case of a woman with HCV-1-related cryoglobulinemic membranoproliferative glomerulonephritis presenting with severe nephritic syndrome and rapidly progressive renal failure, who received successful treatment with the DAA telaprevir in conjunction with PEG-IFN and RBV. Triple therapy was safe and effective, leading to HCV eradication and complete resolution of acute renal failure.

UR - http://www.scopus.com/inward/record.url?scp=84924334445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924334445&partnerID=8YFLogxK

U2 - 10.3851/IMP2684

DO - 10.3851/IMP2684

M3 - Article

VL - 19

SP - 527

EP - 531

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 5

ER -